Suppr超能文献

基于增强型胰蛋白酶的单酶法合成多种双特异性抗体形式

Synthesis of Multiple Bispecific Antibody Formats with Only One Single Enzyme Based on Enhanced Trypsiligase.

机构信息

Department of Naturstoffbiochemie, Institute for Biochemistry and Biotechnology, Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Straße 3a, 06120 Halle (Saale), Germany.

出版信息

Int J Mol Sci. 2022 Mar 15;23(6):3144. doi: 10.3390/ijms23063144.

Abstract

Bispecific antibodies (bsAbs) were first developed in the 1960s and are now emerging as a leading class of immunotherapies for cancer treatment with the potential to further improve clinical efficacy and safety. Many different formats of bsAbs have been established in the last few years, mainly generated genetically. Here we report on a novel, flexible, and fast chemo-enzymatic, as well as purely enzymatic strategies, for generating bispecific antibody fragments by covalent fusion of two functional antibody Fab fragments (Fabs). For the chemo-enzymatic approach, we first modified the single Fabs site-specifically with click anchors using an enhanced Trypsiligase variant (eTl) and afterward converted the modified Fabs into the final heterodimers via click chemistry. Regarding the latter, we used the strain-promoted alkyne-azide cycloaddition (SPAAC) and inverse electron-demand Diels-Alder reaction (IEDDA) click approaches well known for their fast reaction kinetics and fewer side reactions. For applications where the non-natural linkages or hydrophobic click chemistry products might interfere, we developed two purely enzymatic alternatives enabling - to - and - to -terminal coupling of the two Fabs via a native peptide bond. This simple system could be expanded into a modular system, eliminating the need for extensive genetic engineering. The bispecific Fab fragments (bsFabs) produced here to bind the growth factors ErbB2 and ErbB3 with similar K values, such as the sole Fabs. Tested in breast cancer cell lines, we obtained biologically active bsFabs with improved properties compared to its single Fab counterparts.

摘要

双特异性抗体(bsAbs)最早于 20 世纪 60 年代开发,现已成为癌症治疗中免疫疗法的主要类别,具有进一步提高临床疗效和安全性的潜力。在过去的几年中,已经建立了许多不同形式的 bsAbs,主要是通过基因产生的。在这里,我们报告了一种新颖、灵活、快速的化学酶和纯酶策略,通过两个功能抗体 Fab 片段(Fabs)的共价融合来生成双特异性抗体片段。对于化学酶方法,我们首先使用增强型 Trypsiligase 变体(eTl)特异性地对单个 Fab 进行点击锚定修饰,然后通过点击化学将修饰的 Fab 转化为最终的杂二聚体。关于后者,我们使用应变促进炔烃-叠氮化物环加成(SPAAC)和逆电子需求 Diels-Alder 反应(IEDDA)点击方法,这些方法以其快速的反应动力学和较少的副反应而闻名。对于非天然键合或疏水性点击化学产物可能干扰的应用,我们开发了两种纯酶替代方法,能够通过天然肽键实现两个 Fab 的 - 至 - 和 - 至 - 末端偶联。这个简单的系统可以扩展为一个模块化系统,无需进行广泛的基因工程。这里产生的结合生长因子 ErbB2 和 ErbB3 的双特异性 Fab 片段(bsFabs)具有相似的 K 值,与单一 Fab 相似。在乳腺癌细胞系中进行测试时,我们获得了具有改善性质的生物活性 bsFabs,与其单 Fab 对应物相比。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f28/8952323/765adc1619ad/ijms-23-03144-sch001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验